Anti-HIF-1 alpha antibody [EPR16897],Abcam,AB179483

Anti-HIF-1 alpha antibody [EPR16897] (ab179483) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in ChIC/CUT&RUN-seq, ChIP,-seq ICC/IF, IP and WB. First used in a scientific publication in 2016, it is highly cited in over 190 times in peer reviewed journals. Abcam's high quality manufacturing and validation processes ensure Anti-HIF-1 alpha antibody [EPR16897] (ab179483) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Validated for both CUT&RUN and ChIP-seq, which are key applications to map protein-DNA interactions on a genome-wide scale using NGS. The specificity of Anti-HIF-1 alpha antibody [EPR16897] (ab179483) has been confirmed by Western Blot testing in HIF-1 alpha knockout HAP1 cells making its performance in human, mouse and rat samples trusted by the scientific community. Anti-HIF-1 alpha antibody [EPR16897] (ab179483) has 5 independent reviews from customers. Anti-HIF-1 alpha antibody [EPR16897] (ab179483) specifically detects HIF-1 alpha (UniProt ID: Q16665; Molecular weight: 93kDa) and is sold in 100 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone EPR16897 - Anti-HIF-1 alpha antibody [EPR16897] - BSA and Azide freeab221610. Antibody clone EPR16897 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 488, Alexa Fluor® 647 ( ab208419 , ab208420 ). HIF-1 or hypoxia inducible factor 1, is a transcription factor commonly referred to as a ""master regulator of the hypoxic response"" for its central role in the regulation of cellular adaptations to hypoxia. Hypoxia contributes to the pathophysiology of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease. A highly specific HIF-1 alpha antibody, essential for studying hypoxia-inducible factors and oxygen homeostasis. This antibody is crucial in tumor hypoxia research, particularly in understanding cancer progression and angiogenesis. It is widely used in studies of metastasis and HIF-1 alpha inhibitors. Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents. This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .